Research programme: cancer therapeutics - Carrick Therapeutics/Evotec
Latest Information Update: 07 Oct 2016
At a glance
- Originator Carrick Therapeutics
- Developer Carrick Therapeutics; Evotec AG
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Oct 2016 Early research in Cancer in United Kingdom, Ireland, Germany (unspecified route)